Primary bliary crrhosis in pregnancy

Olga Adamczyk-Gruszka, Izabela Lewandowska-Andruszuk, Marzena Wrześniewska, Jakub Gruszka, Karolina Komar-Gruszka


Primary biliary cirrhosis (PBC) is a chronic hepatic condition presumably of immune etiology. In genetically predisposed patients, progressing immunization of the liver is stimulated by environmental or infectious agents. As a result of ill-targeted immune response antimitochondrial autoantibodies M2 (AMA-M2) are produced. They slowly damage fine intrahepatic biliary ducts with typical inflammatory response and subsequent cholestasis, often progressing to hepatic cirrhosis and liver failure, and if it has reached 4 stage, primary hepatic cancer.
PBC is most frequently diagnosed in women after the age of 30. It is 13 times more frequent in females than in males. Currently, PBC is often diagnosed at the asymptomatic stage or when nonspecific symptoms have developed, i.e. fatigue or pruritus. Biochemical tests present elevated cholestatic markers, and immune tests detect elevated autoimmune antibodies AMA and IgM. In advanced cases of hepatic cirrhosis, liver transplant is considered as a final treatment.
Case study

The patient, a 31-year old woman, CI PI, with PBC was first seen in 7 hbd. Her medical history revealed PBC had been diagnosed a year earlier. First clinical symptoms occurred 5 years ago, treated with Proursan. The patient was hospitalized 5 times, i.e. in 30, 36, 37, 38 and 39 hbd, among others, for threatening preterm delivery and cholestasis, and later for liver dysfunction associated with PBC, and for labor. In 39 hbd delivery was induced, and she gave birth (naturally) to a live neonate, female, weighing 2,830g, body length 52 cm, Apgar score 9-10. The liver function improved after the delivery and stabilized. The patient is followed up, treatment with Proursan continued.
Pregnancy in patients with PBC is associated with mother’s exacerbated condition, especially in the third trimester and puerperium. The aforementioned case study shows that with proper care successful management and termination of pregnancy is safe for both mother and her baby.


primary biliary cirrhosis; pregnancy; labor

Full Text:



Abdulkarim AS, Petrovic LM, Kim WR, et al. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol 2004; 40: 380-4.

Ahrens EH, Rayne MA. Primary biliary cirrhosis. Medicine (Baltimore) 1950; 29: 299-306.

Alberts B, Johnson A, Lewis J et al. Molecular Biology of the Cells. Garland Science 2002; 1244-1248.

Axelsson CG, Hallback DA. Twenty-six years of plasma exchange for symptomatic treatment of pruritus in primary biliary cirrhosis. Transfus Apher Sci 2013; 49: 652-4.

Berg CP, Stein GM, Keppeler H et al. Apoptosis-associated antigens recognized by autoantibodies in patients with the autoimmune liver disease primary biliary cirrhosis. Apoptosis 2007.

Bergasa NV, Mason A, Floreani A, Heathcote J. Primary biliary cirrhosis: raport of a focus Study Group. Hepatology 2004; 1013-1020.

Boonstra K, Kunst AE, Stadhouders PH, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-base study. Liver Int 2014 [Epub ahead of print].

Chen RCY, Naiyanetr P, Shu SA, et al. Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology 2013; 57: 1498-508.

Corpechot C, Wendum D. Commentary „Primary biliary cirrhosis: is there still a place for histological evaluation? Clin Res Hepatol Gastroenterol 2013; 37: 556-8.

Dellavance A, Cancado ELR, Abrantes-Lemos CP, et al. Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis. Hepatol Int 2013; 7: 775-84.

Deutsch M, Papatheodoris GV, Tzakou A, Hadziyannis SJ. Risk of hepatocellular carcinoma and extra hepatic malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2008; 20(1): 5-9.

Dohmen K, Shigematsu H, Miyamoto Y, et al. Atrophic corpus gastritis and Helicobacter pylori infection in primary biliary cirrhosis. Dig Dis Sci 2002; 47: 162-9.

Dudkiewicz E, Kryczka W, Horecka-Lewitowicz A, Pierwotna żółciowa marskość wątroby – najczęściej występująca choroba autoimmunizacyjna. Studia Medyczne 2008; 10: 47-52.

European Association for the Study of the Liver. EASL Clinical Practice Guidelins: management of cholestatic liver diseases. J Hepatology 2009; 51: 237-67.

Floreani A, Cazzagon N, Franceschet I, et al. Metabolic syndrome associated with primary biliary cirrhosis. J Clin Gastroenterol 2013 [Epub ahead of print].

Gatselis NK, Zachou K, Norman GL, et al. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity 2013; 46: 471-9.

Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoksycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354: 1053-60.

Habior A, Hartleb M, Milkiewicz P i wsp. Rekomendacje Sekcji Hepatologicznej Polskiego Towarzystwa Gastroenterologii dotyczące postępowania diagnostyczno-terapeutycznego w cholestatycznych chorobach wątroby – adaptacja wytycznych europejskich. Gastroenterol Prakt 2013; 5 (wydanie specjalne).

Hohenester S, Oude-Elferink RPJ, Beuers U. Primary biliary cirrhosis. Semin Immunopathol 2009; 31: 283-307.

Invernizzi P, Gershwin ME. New therapeutics in primary biliary cirrhosis: will there ever be light? Liver Int 2014; 34: 167-70.

Invernizzi P, Selmi C, Poli F, et al. Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology 2008; 48: 1906-12.

Jones DEJ, Watt FE, Metcalf JV, et al. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol 1999; 30: 402-7.

Kakuda Y, Harada K, Sawada-Kitamura S, et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Human Pathol 2013; 44: 1107-17.

Klein R, Kloppel G et al. Antimitochondrial antibody profiles determined at early stages of primary biliaris cirrhosis differentiale between a benign and a progresive course of the disease. Hepatology 1991; 12: 21-27.

Lens S, Leoz M, Nazal L, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 2014; 34: 197-203.

Lindor KD, Gershwin ME, Poupon R, et al. AASLD Practice Guidelines: primary biliary cirrhosis. Hepatology 2009; 50: 291-308.

Mutimer DJ, Fussey SPM, et al. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigenes in primary biliaris cirrhosis. Hepatology 1989; 10: 403-407.

Neuberger J, Thomson R. PBC and AMA. What is the connection? Hepatology 1999; 29: 271-276.

Neuberger J. Recurrent primary biliary cirrhosis. Liver Transplant 2003; 9: 539-46.

Nishio A, Keefe E, Isibashi H, Gershwin E. Diagnosis and treatment of primary biliary cirrhosis. Med Sci Mon 2000; 6: 181-193.

Penner EH. Demonstration of immune complexes containing the ribonucleoprotein antigen Ro in primary biliary cirrhosis. Gastroenterology 1986; 90:

Poupon RE, Chretien Y. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1994; 17: 599-605.

Poupon R. Autoimmune overlaping syndromes. Clin Liver Dis 2003; 7: 865-878.

Selmi C, Balkwill DL, Invernizzi P et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic metabolizing bacterium. Hepatology 2003; 38: 1250-1257.

Sherlock S, Dooley J. Diseases of the liver and biliary tract.Blackwell Science 1997; 10: 239-252.

Silveira MG, Lindor KD. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin Pharmacother 2014 [Epub ahead of print].

Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194: 293-9.

Su TC, Hwang JJ, Kao JH. Hypercholesterolemia in primary biliary cirrhosis. N Engl J Med 2007; 357: 1561-2.

The Merck Manual. Podręcznik diagnostyki i terapii. Beers MH, Porter RS, Jones TV, et al. (eds.). Elsevier Urban & Partner, Wrocław 2008; 276-8.

Tomiyama Y, Takenaka K, Kodama T, et al. Risk factors for survival and the development od hepatocellular carcinoma in patients with primary biliary cirrhosis. Intern Med 2013; 52: 1553-9.

Tsochatzis EA, Feudjo M, Rigamonti C, et al. Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy. Hindawi Publishing Corporation. BioMed Research International. 2013, Article ID 139763.

Tsuda M, Moritoki Y, Lian ZX, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012; 55: 512-21.

Xu L, Sakalian M, Shen Z, et al. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology 2004; 39: 151-6.



  • There are currently no refbacks.

Copyright (c) 2018 © The Author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:

Journal Language(s): English 

PBN Poland



Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2 Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase


Universal Impact Factor 1.78 for year 2012. (

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski